熱門資訊> 正文
Elanco看到合同制造商面临破产影响EBITDA
2024-09-13 21:50
- Elanco Animal Health(ELAN) 0
- iShares LifePath Target Date 2025 ETF USD(ITDA) 0
- Informatica Inc.(NYSE) 0
- Elanco Animal Health (NYSE:ELAN) on Friday disclosed an approximately $5M-$10M impact on its adjusted EBITDA for 2024 after its contract manufacturing supplier TriRx Speke entered administration, a formal insolvency process in the U.K.
- The U.S.-owned TriRx has appointed administrators from FTI Consulting to oversee the process, designed to help financially challenged companies achieve stability.
- The U.S. veterinary products maker Elanco (ELAN) has a long-term supply pact with the Liverpool pharmaceutical plant to manufacture certain farm animal products.
- “Elanco is working constructively with the Administrators to support business continuity in the interim and explore possible options in the best interest of all stakeholders,” the company said, adding that it expects minimal supply disruption as a result.
- However, Elanco (ELAN) continues to expect its 2024 adjusted EBITDA will reach $900M-$940M.
More on Elanco
- Elanco Animal Health: Positioned For Success
- Elanco Animal Health (ELAN) Q2 2024 Earnings Call Transcript
- Elanco: Expect Solid Growth From 6 Blockbusters Despite Execution Uncertainty
- Elanco spikes as CEO buys over $1M stock
- Elanco Non-GAAP EPS of $0.30 beats by $0.06, revenue of $1.18B beats by $30M
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
